Amongst the better-known cancer immunotherapies are immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs). The discovery and development of ICIs has been revolutionary for cancer therapy and has led to a paradigm shift. Therapeutic success of US Food and Drug Administration (FDA) approved ICIs Keytruda 5 (pembrolizumab; Merck & Co.) and Opdivo (nivolumab; Bristol Myers Squibb) in treating melanoma and non-small cell lung cancer (NSCLC) among other types of cancer has been encouraging. Besides ICIs, US FDA approved ADCs such as Kadcyla 10 (ado-trastuzumab emtansine; Genentech Inc.), Besponsa 11 (inotuzumab ozogamicin; Pfizer Inc.) and Elahere 12 (mirvetuximab soravtansine; ImmunoGen Inc.) have also shown tremendous success in the treatment of metastatic breast cancer, 13 acute lymphoblastic leukemia and ovarian cancer, respectively. The remarkable success of ADCs 16 has meant that the scope of ADCs is expanding beyond the boundaries of cancer.